87666-83-9Relevant articles and documents
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl) propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist
Dwyer, Michael P.,Yu, Younong,Chao, Jianping,Aki, Cynthia,Chao, Jianhua,Biju, Purakkattle,Girijavallabhan, Viyyoor,Rindgen, Diane,Bond, Richard,Mayer-Ezel, Rosemary,Jakway, James,Hipkin, R. William,Fossetta, James,Gonsiorek, Waldemar,Bian, Hong,Fan, Xuedong,Terminelli, Carol,Fine, Jay,Lundell, Daniel,Merritt, J. Robert,Rokosz, Laura L.,Kaiser, Bernd,Li, Ge,Wang, Wei,Stauffer, Tara,Ozgur, Lynne,Baldwin, John,Taveras, Arthur G.
, p. 7603 - 7606 (2007/10/03)
Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.